NDA 020597 · Upjohn
Xalatan
Latanoprost · Ophthalmic · Prostaglandin Analog
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Dec 19, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Jun 5, 1996
Approved uses
2
Original approval plus efficacy supplements
Registered trials
253
56 Phase 3, 9 recruiting
FAERS reports
50,175
27,826 serious, 3,136 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 15, 2024.
Latanoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Latanoprost ophthalmic solution is a prostaglandin F 2α analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. ( 1 )
Mechanism: Latanoprost is a prostaglandin F 2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 20, 2002 Supplement 10 · Efficacy · priority review LabelLetter
- Jun 5, 1996 Original approval · Type 1 - New Molecular Entity · priority review Review
1 products under this application
- XALATAN · LATANOPROST 0.005% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT
Clinical trials
Interventional ClinicalTrials.gov studies with "Latanoprost" as an intervention, any sponsor and status, largest first.
- Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Aerie PharmaceuticalsIndustry
NCT02674854 · 750 participants · Start Feb 2016 · Primary completion Mar 2017
Drug: PG324 Ophthalmic Solution 0.02%/0.005%; Netarsudil (AR-13324) ophthalmic solution 0.02% and 1 more · For: Open-angle Glaucoma; Ocular Hypertension
Sites: Bedminster, New Jersey
- Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Alcon ResearchIndustry
NCT00690794 · 726 participants · Start Jul 2008 · Primary completion May 2009
Drug: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®); Latanoprost ophthalmic solution 0.005% (XALATAN®) · For: Open-angle Glaucoma; Ocular Hypertension
- Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Aerie PharmaceuticalsIndustry
NCT02558400 · 718 participants · Start Sep 18, 2015 · Primary completion May 17, 2017
Drug: PG324 Ophthalmic Solution 0.02%/0.005%; Netarsudil (AR-13324) Ophthalmic Solution 0.02% and 1 more · For: Open-angle Glaucoma; Ocular Hypertension
Sites: Bedminster, New Jersey
- Phase III Clinical Trial of TRAVATAN Z in Ocular Surface HealthPivotal-lookingCompleted
Alcon ResearchIndustry
NCT00761319 · 705 participants · Start Oct 2008 · Primary completion Sep 2009
Drug: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®); Latanoprost ophthalmic solution 0.005% (XALATAN®) · For: Open-angle Glaucoma; Ocular Hypertension
- MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Nicox Ophthalmics, Inc.Industry
NCT04630808 · 696 participants · Start Nov 9, 2020 · Primary completion Apr 11, 2025
Drug: NCX 470 0.1%; Latanoprost 0.005% · For: Open Angle Glaucoma; Ocular Hypertension
Sites: Dothan, Alabama; Chandler, Arizona; Phoenix, Arizona · 88 sites in all
- Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Nicox Ophthalmics, Inc.Industry
NCT04445519 · 691 participants · Start Jun 1, 2020 · Primary completion Sep 16, 2022
Drug: NCX 470 0.065% (initial phase of trial); Latanoprost 0.005% (initial phase of trial) and 3 more · For: Open Angle Glaucoma; Ocular Hypertension
Sites: Newport Beach, California
- Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Nicox Ophthalmics, Inc.Industry
NCT03657797 · 656 participants · Start Aug 1, 2018 · Primary completion Aug 23, 2019
Drug: NCX 470; Latanoprost 0.005% · For: Glaucoma, Open-Angle; Hypertension, Ocular
Sites: Austin, Texas
- Next Generation RocklatanPivotal-lookingCompleted
Alcon ResearchIndustry
NCT06441643 · 646 participants · Start Sep 4, 2024 · Primary completion Nov 14, 2025
Drug: AR-17043 Ophthalmic Solution; PG043 Ophthalmic Solution and 4 more · For: Open Angle Glaucoma; Ocular Hypertension
Sites: Dothan, Alabama; Phoenix, Arizona; Garden Grove, California · 25 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- treatment failure5,934
- drug ineffective3,267
- fatigue2,378
- eye irritation2,178
- headache1,837
- intraocular pressure increased1,787
- dyspnoea1,678
- diarrhoea1,676
- dizziness1,655
- off label use1,647
- eye pain1,642
- death1,620
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 427 |
| 2005 | 616 |
| 2006 | 656 |
| 2007 | 703 |
| 2008 | 719 |
| 2009 | 834 |
| 2010 | 2,052 |
| 2011 | 1,687 |
| 2012 | 1,971 |
| 2013 | 1,643 |
| 2014 | 1,876 |
| 2015 | 2,271 |
| 2016 | 2,722 |
| 2017 | 2,570 |
| 2018 | 2,846 |
| 2019 | 3,051 |
| 2020 | 8,873 |
| 2021 | 2,408 |
| 2022 | 2,369 |
| 2023 | 2,431 |
| 2024 | 2,481 |
| 2025 | 2,766 |
| 2026 | 2,203 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xalatan (Latanoprost)
2024 spending
$4.9M
Beneficiaries
2,384
10,322 claims
Per beneficiary
$2,049
$97.68 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $8,408,259 |
| 2021 | $6,460,872 |
| 2022 | $5,673,411 |
| 2023 | $5,429,444 |
| 2024 | $4,884,115 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
Li T, Lindsley K, Rouse B, et al. · Ophthalmology 2016 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension.
Stalmans I, Lim KS, Oddone F, et al. · Graefes Arch Clin Exp Ophthalmol 2024 · Randomized Controlled Trial, Multicenter Study
- Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis.
Quaranta L, Biagioli E, Riva I, et al. · J Ocul Pharmacol Ther 2013 · Comparative Study, Meta-Analysis
- Effect of Latanoprost on Choroidal Thickness.
Sahinoglu-Keskek N, Canan H · J Glaucoma 2018 · Clinical Trial
- Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial.
Higginbotham EJ, Feldman R, Stiles M, et al. · Arch Ophthalmol 2002 · Clinical Trial, Comparative Study
- The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: A systematic review and meta-analysis.
Xing Y, Zhu L, Zhang K, et al. · PLoS One 2020 · Meta-Analysis, Systematic Review
Sponsor: Upjohn
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.